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Abstract
Objective: The development of ciliochoroidal effusions and secondary acute angle-closure crisis (AACC) is an
uncommon side effect of topiramate, a common antiepileptic now FDA-approved for migraine prophylaxis. The
mechanisms that underlie the development of ciliochoroidal effusions after topiramate use remain unclear.
Materials and Methods: Ultrasound biomicroscopy (UBM) was also performed in all participants after stopping
topiramate.
Results: Six patient cases are presented with medication-induced AACC following the initiation or escalation of
topiramate. Ciliochoroidal effusions were confirmed by gray-scale sonography in all patients at presentation. The
images revealed either plateau iris configuration or atypical plateau iris configuration. Plateau iris configuration is
defined by presence of an anteriorly rotated ciliary body processes and an absent posterior sulcus. Atypical plateau
iris configuration refers to when the iris inserts directly into the ciliary body face.
This case series, of medication-induced angle-closure crisis, suggests that plateau iris configuration is a shared
anatomical feature in the development of topiramate-induced ciliochoroidal effusions.
Keywords
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Topiramate (Topamax™) is a sulfa-derivative monosaccharide that was first approved for use as an antiepileptic
medication in 1996.1 It has been gaining popularity for its
use in nonepileptic conditions, including bipolar personality disorder,2,3 alcohol dependence,4 smoking cessation,5
and migraine prophylaxis.6 In 2012, evidence-based
guidelines on episodic migraine prevention were updated
with topiramate indicated as a first-tier treatment option.7,8
With over 8.5 million prescriptions a year per the Agency
for Healthcare Research and Quality Survey, topiramate
was reported as the 89th most prescribed drug as of 2018.9
As the range of indications for topiramate’s use
has continued to expand, the prevalence of topiramateinduced adverse effects has concomitantly increased.
Although rare, with only 23 reported cases out of approximately 825,000 users in a post-marketing surveillance
report,10-12 complications of myopic shift and acute angleclosure glaucoma secondary to ciliochoroidal effusions
are a known side effect with potentially devastating consequences to vision.13 Ciliochoroidal effusions have been
associated with other sulfa derivatives as well, including

sulfamethiozole, acetazolamide, and sulfapyridine.14
In this study, the intent was to demonstrate that ultrasound biomicroscopy (UBM) was an important test.
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Furthermore, it was important to demonstrate that six
cases of topiramate-induced ciliochoroidal effusions
were all found to have underlying typical plateau iris
(PIC) or atypical plateau iris configuration (APIC), after
resolution of the ciliochoroidal effusions.

Materials and Methods
This was a retrospective review of patients seen at the
W.K. Kellogg Eye Center, University of Michigan with
topiramate-induced ciliochoroidal effusion between May
2005 and November 2017. Approval from the University
of Michigan Institutional Review Board was obtained,
and the study followed the tenets set forth by the
Declaration of Helsinki. Participants were included in
the study if they met the following criteria: clinically significant ciliochoroidal effusions after using topiramate
(Topamax™), and had ultrasound imaging during their
clinical course. Exclusion criteria included ocular disease
or condition that had the potential to affect angle anatomy, including prior penetrating trauma, prior anterior
segment surgery (excluding cataract surgery), nanophthalmos (<21.0 mm axial length), or uveitis.
The primary outcome measure of this study was angle
morphology on UBM after resolution of the effusions.
Secondary outcome findings included duration of topiramate usage before symptom onset, demographic information including sex and age, and symptoms on presentation.
The ultrasound equipment system with transducers to
image the eye is shown in Figure 1. Representative structures of the anterior segment of a normal eye, forms of
PIC (ie, typical and atypical), and plateau iris syndrome
with angle closure are shown in Figure 2.

Results
Eight patients presented with topiramate-induced choroidal effusions, but two patients were excluded from the
review due to prior diagnoses uveitis and nanophthalmos.
The average age of onset among the remaining six
patients was 42 ± 7.9 years (range = 32–52). The majority (5/6 cases, 83%) were female, and all identified as
non-Hispanic white (Table 1). The most common reason
for using topiramate was for migraine prophylaxis (4/6
cases, 67%) (Table 2). The average time between medication start or dosage increase and symptom onset was 13
± 2.7 days (range = 8–14).
The most common presenting symptom was blurred
vision (6/6 cases, 100%) (Table 2). Cases 2, 3, and 4 (3/6
cases, 50%) presented in angle-closure crisis of both
eyes. We were unable to obtain the records from Case 3’s
presenting emergency room visit; the IOP was within
normal limits on maximum medical therapy upon evaluation by our clinic. The other two cases had an average
presenting IOP of 49 (range = 38–60), which was

Figure 1. This figure shows a typical ultrasound instrument
with ultrasound transducers (Quantel Absolu, Bozeman,
MT) used to image ocular structures. On the left side of the
monitor, there is a 20 mHz transducer used for posterior
segment imaging. On the right side of the monitor, there is
a 15 mHz transduer (left) also used for posterior segment
imaging and a 50 mHz transducer with a green sleeved cover
filled with solution used for anterior segment imaging (right).

medically managed until resolution of the effusions. All
three cases received a topical cycloplegic (atropine 1% or
cyclopentolate 1%), a topical carbonic anhydrase inhibitor (dorzolamide 2% or brinzolamide 1%), timolol 0.5%,
and brimonidine 0.2%. Two cases were also prescribed
500 mg extended release oral acetazolamide twice per
day. Case 3 had bilateral laser peripheral iridotomies
prior to presentation, which had no effect on the IOP. No
incisional surgeries were performed.
Cases 1, 5, and 6 had normal IOP on presentation
(mean = 17, range = 10–20), but were all documented to
have narrow angles and a shallow peripheral anterior
chamber on examination. Case 5 had an isolated and
painless acute 5-diopter myopic shift.
Five cases had a gray-scale imaging at the time of
diagnosis demonstrating active ciliochoroidal effusions,
and four had a UBM demonstrating the anterior ciliochoroidal effusions (Figure 3). Case 3 was initially diagnosed
and treated at an outside facility, with resolution at the
time of referral. Case 5 was seen over the weekend when
UBM was not available, and had complete resolution at
the time of the Monday follow-up appointment. All cases
were seen in follow-up after resolution of symptoms, and
all had documented ciliochoroidal effusion resolution by
sonographic exam. Later recall of these cases showed
typical or atypical PIC by UBM (Figure 3).

Discussion
In this study, 100% of cases seen at the Kellogg Eye
Center had evidence of typical PIC or atypical PIC on
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Figure 2. Ultrasound biomicroscopy images of anterior segment angle. Image A shows normal anatomy showing cornea [c],
open angle [a], iris [i], portion of crystalline lens [l], ciliary sulcus [•], ciliary body [cb] process, and sclera [s]. Image B shows
typical plateau iris configuration with narrow angle compared with A, absent ciliary sulcus compared with A, and anterior
rotation of the ciliary body process. Image C shows atypical plateau iris configuration with open angle, iris root inserted on ciliary
body, absent ciliary sulcus, and anterior rotation of the ciliary body process. Image D shows plateau iris syndrome with closed
angle, absent ciliary sulcus, and anterior rotation of the ciliary body process.
Table 1. Characteristics of Patients With Topiramate-Induced Ciliochoroidal Effusions (N = 6) Demonstrates a Caucasian
Female Predominance With an Average Age of Onset of 41.8 Years.

Sex
Male
Female
Race
White
Other
Ethnicity
Non-Hispanic
Hispanic
Other
Age
Past ocular history
None
Refractive error
Cataracts
ABMD
Ocular hypertension
Total

Number (N = 6)

%

1
5

83
17

6
0

100
0

6
0
0
—

0
0
0
—

2
2
1
1
1
6

33
33
17
17
17
100

Abbreviation: ABMD, anterior basement membrane dystrophy.

Range

Mean

32–52 years

42 (±7.1)
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Table 2. Presenting Characteristics of Topiramate-Induced Ciliochoroidal Effusions, Including Reason for Medication Use.
There Is No Data on the Initial Presenting Intraocular Pressure of Case 3; This Patient Presented to Us With Normal Intraocular
Pressure on Maximum Medical Therapy, Including Diamox. Several Patients Had More Than One Presenting Symptom and Were
Placed on More Than One Medications.
Number (N = 6)

%

Range

Mean

Reason for topiramate use
Migraine headaches
4
67
Grand mal seizures
2
33
Number of days after medication start or dosage change when symptoms occurred
Presenting symptoms
Blurred vision
Headache
Eye pain
Myopic shift
Photophobia
Presenting IOP
Acute angle closure
Narrow but open
Unknown (not available)
Treatment
Atropine
Cyclopentolate
Brimonidine
Timolol
Dorzolamide
PO acetazolamide
Prednioslone
Observation
Laser peripheral iridotomy
Incisional surgery
PIC or atypical plateau iris configuration
by ultrasound biomicroscopy
Total

6
3
3
2
2

100
50
50
33
33

2
3
1

33
50
17

2
1
3
3
3
2
1
2
0
-0
6

33
17
50
50
50
33
17
33
0.0
0.0
100

6

100

8–14 days

12

38–60 mmHg
12–20 mmHg
—

49
17
—

Abbreviations: IOP, intraocular pressure; PIC, plateau iris configuration; PO, per os.

UBM testing following topiramate cessation and resolution of the ciliochoroidal effusions. There have been three
separate case reports of medication-induced ciliochoroidal effusions that occurred in patients with typical or
atypical PIC.15-17 The most recent case reported by
Agarwal showed UBM images during the topiramateinduced ciliochoroidal effusion and after the resolution of
the ciliochoroidal effusion. While it is difficult to estimate the frequency of such idiosyncratic drug reactions, a
recent health services research project reported that
angle-closure glaucoma among individuals using topiramate was estimated at one out of every 2505 new topiramate users.18 In this health services data set based upon
billing codes, there were no clinical gonioscopy data or
ultrasound testing to determine the presence of typical or
atypical PIC. While this small number of cases is inadequate to suggest an association between this angle anatomy and idiosyncratic drug reaction with ciliochoroidal

effusions, it is certainly curious that these cumulative
nine cases of drug-associated ciliochoroidal effusions
share a common ultrasound imaging finding of typical or
atypical PIC.
The term PIC is defined as the presence of anteriorly
positioned ciliary processes that results in a narrow or
absent ciliary sulcus. The term atypical PIC was proposed
by Man et al. to describe a similar configuration of anteriorly rotated ciliary processes with iris root insertion into
the top of the ciliary processes, rather than into the
angle.16 Using UBM in conjunction with the examination, PIC was found to have a prevalence up to 37.0% in
patients with chronic primary angle-closure glaucoma
and 19.2% in patients with open-angle glaucoma.19
The reasons for why typical or atypical PIC may be
associated with such idiosyncratic drug-induced ciliochoroidal effusions is not understood but may lie in the fluid
balance of the uveal tissues in the eye. Quigley proposed
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Figure 3. Ultrasound imaging of cases during active ciliochoroidal effusions and after resolution showing the anterior segment
by UBM and the posterior segment with gray-scale imaging. Case 1, active effusions have the UBM image showing the cornea
[c], iris [i], portion of crystalline lens [l], absent ciliary sulcus [not shown], ciliary body [cb] process, sclera [s], and [*] shows the
effusion which looks like a “dark line.” Case 1, active effusions, gray-scale image showing the thin retina [r] and [*] shows the
effusion which looks like a “dark line.” Case 1, after resolution shows the same structures and no effusion in both the UBM and
gray-scale images. In addition, all of the after resolution UBM images show plateau iris.
Abbreviation: UBM, ultrasound biomicroscopy.

that the fluid balance of the iris may play a pivotal role in
the risk for acute angle-closure crises in subjects with
narrow angles.20 Although initially thought to be the
result of an osmotic disturbance with the lens resulting in
swelling and shallowing of the anterior chamber, Craig

et al. reported that lens swelling only accounted for a
small portion of shallowing (9%–16%) and instead, was
predominantly due to ciliochoroidal effusion.21 Another
study by Hesami et al. further supported these findings as
significant increases in myopia were reported in patients

Shen et al
following a month of topiramate use while reporting no
significant changes in anterior chamber angle, depth, or
volume.22 While the relationship of this typical or atypical PIC and intraocular fluid balance is not known, the
potential role of this anatomical configuration in these
idiosyncratic drug reactions with ciliochoroidal effusions
is of interest going forward by using ultrasound imaging
to evaluate this anatomical configuration after resolution
of these medication-associated ciliochoroidal effusions.
With this additional examination of these uncommon
idiosyncratic reactions, it may be possible to model the
relative risk for such medication-induced ciliochoroidal
effusions.
There are several limitations of this study that include
a small number of cases of topiramate-induced ciliochoroidal effusions. While it was considered a comprehensive medical record search to identify more cases, this
approach was challenging as there are no ICD-9 or ICD10 codes specific for ciliochoroidal effusions and adverse
drug reaction. Although the included list is meant to be
comprehensive, it is possible that the six cases do not
include every case seen at the University of Michigan
during this time period described in the methods. As the
case series is retrospective and encompasses patients seen
by multiple providers in different subspecialties and clinics, dynamic gonioscopy was not always performed to
determine the presence of plateau iris. Due to this limitation, UBM imaging was used to determine the anatomical
configuration of typical or atypical PIC after resolution of
the ciliochoroidal effusions.

Conclusion
In summary, UBM imaging after resolution of topiramate-induced ciliochoroidal effusions demonstrated that
all six cases had typical or atypical PIC. To the best of our
knowledge, this is the largest case series to identify a
shared structural anatomy of typical or atypical PIC in
this idiosyncratic drug reaction of topiramate-induced
ciliochoroidal effusions. Agarwal’s case study on topiramate-induced ciliochoroidal effusions also demonstrated
PIC by UBM imaging.17 While these combined cases
showed typical or atypical PIC by UBM after resolution
of the drug-induced ciliochoroidal effusions, follow-up
imaging after resolution is needed to generate additional
data on this observation. While this concordance between
typical or atypical PIC and medication-induced ciliochoroidal effusions is limited to these new six cases and one
recent case report,17 if the clinician is knowledgeable of
typical or atypical PIC in a patient, who has medical
conditions treated with topiramate, then it is reasonable to advise such patients of this potential relationship. As these cases report reversal of this idiosyncratic
reaction after stopping topiramate, informing the signs
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and symptoms to these patients, who have known typical
or atypical PIC, is prudent. At the very least, it is our
responsibility to educate patients of the possibility of this
uncommon idiosyncratic condition, especially in patients
who may already be noted to have this underlying angle
anatomy of typical or atypical PIC.
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